Clinical Trial

Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer

Paul A Cohen, Penelope M Webb, Madeleine King, Andreas Obermair, Val Gebski, Phyllis Butow, Rachael Morton, Wanda Lawson, Patsy Yates, Rachel Campbell, Tarek Meniawy, Michelle McMullen, Andrew Dean, Jeffrey Goh, Orla McNally, Linda Mileshkin, Philip Beale, Rhonda Beach, Jane Hill, Cyril Dixon, Sue Hegarty, Jim Codde, Angela Ives, Yeh Chen Lee, Alison Brand, Anne Mellon, Sanela Bilic, Isobel Black, Stephanie Jeffares, Michael Friedlander

10.1136/ijgc-2021-002999

September 22, 2021

Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR)

Faiza Gaba, Nicolò Bizzarri, Paul Kamfwa, Allison Saiz, Oleg Blyuss, Shantini Paranjothy, Pedro T Ramirez, David Cibula, on behalf of the GO SOAR Team, Mohamedraed Elshami, Mahmoud Saad, Ahmed Nafea, Muhammed Elhadi, Alaa Ismail, Hamza Al-Naggar, Darin Maria Cecilia, Maximilian Lanner, Andrei Pletnev, Basel Refky, Abdelazez Elkady, Tarek Karkour, Hazim Salah Ali, Sherief Ghozy, Sameh Daghash, Mohamed Hamed Elmelegy, Eman Monier, Mohammad Abdel-Rahman Mohammad, Domenico Ferraioli, Tanja Nikolova, Stamatios Petousis, Charalampos Theofanakis, Jagannth Mishra, Vadaparty Annapurna, Mariam Anjum Ifthikar, Anik Ghosh, Ajay Chanakya Vallabhaneni, Bijoy Kar, Alyaa Al-khafaji, Ali Al-Isawi, Michael O’Leary, Fabio Martinelli, Martina Arcieri, Stefano Restaino, Anna Fagotti, Edoardo Cola, Stefano Bogliolo, Qais Shatnawi, Aya Zazo, Amer Mahmoud Sindiani, Wafa Alsardieh, Abdulrahman Qasem, Shatha Husain, Maherah Kamarudin, Moniba Korch, Ishak Lawal, Adeyemi Okunowo, Mohammed Alkronz, Victor Lago, Amani Alsattari, Khalil Abuzaina, Farah Shahin, Ayat Aljuba, Waleed Abu Hatab, Najib Salameh, Adnan Radi, João Casanova, Kamil Zalewski, Amel Yousif, Igor Govorov, Ahmed Abu-Zaid, Susan Alghamdi, Antonio Gil Moreno, Natalia Rodriguez, Felix Boria, Zoia Razumova, Zuheir Alshehabi, Bassam Hassan, Hamdi Nawfal, Amr Hamza, Seda Şahin Aker, Salih Taskin, Ilker Kahramanoglu, Ilker Selcuk, Mahalakshmi Gurumurthy, Mary Cairns, Lori McPherson, Sadaf Ghaem-Maghami, John Butler, Christine Ang, Aarti Sharma, Hamza Al-Naggar, Sara Saif, Noor Abualdahab, Shohra Qaderi, Swali V Fundafunda, Mohammed Awad, Lina Karout, Mohamad B Kassab, Ali Safar, Reem Abdallah, Sana Hatoum, Said Mohamad Elmakkaoui, Rania Itani, Jihad El Hassan, Samar Karout, Hussein Mansour Jamal Edine, David Atallah, Salah Eddine Oussama Kacimi, Mustafa Mohamed, Chee Yang Tan, Hanan Haidar, Wafaa Shehada, Hisham Ahmed Abou-Taleb, Mohamed O. Herdan, Ali Hussien Ali, Ahmed Ragab Ali Ahmed, Omar Salah Ibrahim Mohamed, Mohamed I Omar, Eman Ibrahim Zineldin, Ahmed Sabry Fouad El-hamouly, Baraa N. Hajjaj, Shukri Odeh Yousef, Besan Shaheen, Akram Elhossini, Ziena Obiedat, Maen Alsumadi, Bisan Ahmed, Salsabeel Abed, Akram Husaini, Subhi Maher Abusharkh, Martina Aida Angeles

10.1136/ijgc-2021-002586

September 6, 2021

Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)

Günter Emons, Jae-Weon Kim, Karin Weide, Nikolaus de Gregorio, Pauline Wimberger, Fabian Trillsch, Boris Gabriel, Dominik Denschlag, Stefan Kommoss, Mustafa Aydogdu, Thomas Papathemelis, Martina Gropp-Meier, Mustafa-Zelal Muallem, Cristin Kühn, Andreas Müller, Matthias Frank, Michael Weigel, Holger Bronger, Björn Lampe, Jörn Rau, Carmen Schade-Brittinger, Philipp Harter

10.1136/ijgc-2021-002703

July 5, 2021

A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

Antonio Gonzalez Martin, Luisa Sanchez Lorenzo, Nicoletta Colombo, René dePont Christensen, Florian Heitz, Mihai Meirovitz, Frederic Selle, Toon van Gorp, Nuria Alvarez, Javier Sanchez, Carmen Marqués

10.1136/ijgc-2020-001633

December 14, 2020